Cargando…
Cathepsin B Deficiency Improves Memory Deficits and Reduces Amyloid-β in hAβPP Mouse Models Representing the Major Sporadic Alzheimer’s Disease Condition
The lysosomal cysteine protease cathepsin B (CTSB) has been suggested as a biomarker for Alzheimer’s disease (AD) because elevated serum CTSB in AD patients has been found to correlate with cognitive dysfunction. Furthermore, CTSB gene knockout (KO) in non-transgenic and transgenic AD animal models...
Autores principales: | Hook, Gregory, Kindy, Mark, Hook, Vivian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185432/ https://www.ncbi.nlm.nih.gov/pubmed/36970896 http://dx.doi.org/10.3233/JAD-221005 |
Ejemplares similares
-
Cathepsin B is a New Drug Target for Traumatic Brain Injury Therapeutics: Evidence for E64d as a Promising Lead Drug Candidate
por: Hook, Gregory, et al.
Publicado: (2015) -
Amyloid β Modification: A Key to the Sporadic Alzheimer's Disease?
por: Barykin, Evgeny P., et al.
Publicado: (2017) -
Human brain gene expression profiles of the cathepsin V and cathepsin L cysteine proteases, with the PC1/3 and PC2 serine proteases, involved in neuropeptide production
por: Podvin, Sonia, et al.
Publicado: (2018) -
Melatonin reduces β-amyloid accumulation and improves short-term memory in streptozotocin-induced sporadic Alzheimer’s disease model
por: Andrade, Marcos K., et al.
Publicado: (2023) -
Cathepsin D: A Candidate Link between Amyloid β-protein and Tauopathy in Alzheimer Disease
por: Suire, Caitlin N., et al.
Publicado: (2021)